Borderline diabetic: Screened based on fasting blood glucose levels from 110 mg/dl and below 126 mg/dl, or HbA1c(NGSP) levels from 6.2% and below 6.5%. High LDL-C subject: LDL-C levels from 120 mg/dl and below 160 mg/dl.
Conditions
Interventions
Intervention type:DRUG,BEHAVIOUR
Name of intervention:allulose
Dose form / Japanese Medical Device Nomenclature:SYRUP
Route of administration / Site of application:ORAL
Dose per administration:5g, 15g
Sponsors
Matsutani Chemical Industry Co., Ltd.
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: Borderline diabetic: Screened based on fasting blood glucose levels from 110 mg/dl and below 126 mg/dl, or HbA1c(NGSP) levels from 6.2% and below 6.5%. High LDL-C subject: LDL-C levels from 120 mg/dl and below 160 mg/dl.
Exclusion criteria
Exclusion criteria: 1. Individuals suffering from serious diseases 2. Individuals had intestinal surgeries 3. Individuals using medications to control blood glucose and lipid levels 4. Individuals how are allergic to oligosaccharides and sweeteners 5. Individuals using functional foods to control blood glucose and lipid levels 6. Individuals participate in other clinical trials (food material, medicine, cosmetics, liniment)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum lipids of up to 24 hours after ingestion (triglyceride, cholesterol, apoprotein) | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood glucose and insulin levels of up to 24 hours after ingestion | — |
Countries
Japan
Contacts
Public ContactNoriko Hayashi
Matsutani Chemical Industry Co., Ltd.
Outcome results
None listed